PolyPid (NASDAQ:PYPD) specializes in developing extended-release drugs with a primary focus on preventing surgical site infections and promoting bone growth. The company is recognized for its innovative PLEX technology platform, a unique delivery system that allows for a controlled release of drugs over extended periods, improving patient outcomes and reducing healthcare costs. Through its flagship projects, D-PLEX100 for surgical site infections and BONEX for bone regeneration, PolyPid aims to address critical unmet medical needs in the surgical and orthopedic sectors. Its mission is centered on enhancing recovery and reducing complications associated with surgeries, thereby improving the quality of life for patients worldwide.